A critical review of anagrelide therapy in essential thrombocythemia and related disorders

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Thrombocytosis is a common clinical problem and it represents either a primary myeloid disorder (a clonal process) or a reactive phenomenon. While reactive thrombocytosis is often inconsequential, clonal thrombocytosis may require cytoreductive therapy to prevent thrombohemorrhagic complications. In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET). Despite the absence of similar evidence for clinical benefit, the platelet-lowering agent anagrelide has been widely used in both ET and polycythemia vera (PV) and recent reports of serious side-effects suggest that such practice might be detrimental to patients. In the current review we provide basic drug information as well as a critical assessment of anagrelide treatment in ET and related disorders.

Original languageEnglish (US)
Pages (from-to)641-650
Number of pages10
JournalLeukemia and Lymphoma
Volume46
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Essential Thrombocythemia
Thrombocytosis
Polycythemia Vera
Hydroxyurea
Controlled Clinical Trials
Thrombosis
Therapeutics
Blood Platelets
Pharmaceutical Preparations
anagrelide

Keywords

  • Anagrelide
  • Chemotherpy
  • Essential thrombocythemia
  • Myeloproliferative disorders

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A critical review of anagrelide therapy in essential thrombocythemia and related disorders. / Dingli, David M; Tefferi, Ayalew.

In: Leukemia and Lymphoma, Vol. 46, No. 5, 05.2005, p. 641-650.

Research output: Contribution to journalArticle

@article{9d5cf3fbae90473bb678c5a3dbbedfa4,
title = "A critical review of anagrelide therapy in essential thrombocythemia and related disorders",
abstract = "Thrombocytosis is a common clinical problem and it represents either a primary myeloid disorder (a clonal process) or a reactive phenomenon. While reactive thrombocytosis is often inconsequential, clonal thrombocytosis may require cytoreductive therapy to prevent thrombohemorrhagic complications. In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET). Despite the absence of similar evidence for clinical benefit, the platelet-lowering agent anagrelide has been widely used in both ET and polycythemia vera (PV) and recent reports of serious side-effects suggest that such practice might be detrimental to patients. In the current review we provide basic drug information as well as a critical assessment of anagrelide treatment in ET and related disorders.",
keywords = "Anagrelide, Chemotherpy, Essential thrombocythemia, Myeloproliferative disorders",
author = "Dingli, {David M} and Ayalew Tefferi",
year = "2005",
month = "5",
doi = "10.1080/10428190400029817",
language = "English (US)",
volume = "46",
pages = "641--650",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A critical review of anagrelide therapy in essential thrombocythemia and related disorders

AU - Dingli, David M

AU - Tefferi, Ayalew

PY - 2005/5

Y1 - 2005/5

N2 - Thrombocytosis is a common clinical problem and it represents either a primary myeloid disorder (a clonal process) or a reactive phenomenon. While reactive thrombocytosis is often inconsequential, clonal thrombocytosis may require cytoreductive therapy to prevent thrombohemorrhagic complications. In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET). Despite the absence of similar evidence for clinical benefit, the platelet-lowering agent anagrelide has been widely used in both ET and polycythemia vera (PV) and recent reports of serious side-effects suggest that such practice might be detrimental to patients. In the current review we provide basic drug information as well as a critical assessment of anagrelide treatment in ET and related disorders.

AB - Thrombocytosis is a common clinical problem and it represents either a primary myeloid disorder (a clonal process) or a reactive phenomenon. While reactive thrombocytosis is often inconsequential, clonal thrombocytosis may require cytoreductive therapy to prevent thrombohemorrhagic complications. In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET). Despite the absence of similar evidence for clinical benefit, the platelet-lowering agent anagrelide has been widely used in both ET and polycythemia vera (PV) and recent reports of serious side-effects suggest that such practice might be detrimental to patients. In the current review we provide basic drug information as well as a critical assessment of anagrelide treatment in ET and related disorders.

KW - Anagrelide

KW - Chemotherpy

KW - Essential thrombocythemia

KW - Myeloproliferative disorders

UR - http://www.scopus.com/inward/record.url?scp=20144379068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144379068&partnerID=8YFLogxK

U2 - 10.1080/10428190400029817

DO - 10.1080/10428190400029817

M3 - Article

VL - 46

SP - 641

EP - 650

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -